FDA issued an emergency use authorization to George Washington University Public Health Laboratory for its GWU SARS-CoV-2 RT-PCR Test. This molecular test is for use by healthcare providers for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens (for example, nasal, mid-turbinate, nasopharyngeal, and oropharyngeal swabs) from individuals suspected of having contracted covid-19. Administration of this test is limited to the George Washington University Public Health Laboratory.

To date, the FDA has currently authorized 208 tests under EUAs; these include 169 molecular tests, 37 antibody tests, and 2 antigen tests.

For more information, visit FDA.